Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia
Submission to EMA follows Biologics Licensing Application submission to U.S. FDA earlier this month SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene…